Modality
Multispecific
MOA
BTKi
Target
PCSK9
Pathway
Innate Imm
PompeSLEPsA
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
~Jun 2021
→ ~Sep 2022
Phase 3
Dec 2022
→ Mar 2030
Phase 3Current
NCT07323053
30 pts·SLE
2022-12→2030-03·Not yet recruiting
30 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-165mo agoEnrollment Complete· PsA
2030-03-093.9y awayPh3 Readout· SLE
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Not yet…
Catalysts
Enrollment Complete
2025-10-16 · 5mo ago
PsA
Ph3 Readout
2030-03-09 · 3.9y away
SLE
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07323053 | Phase 3 | SLE | Not yet recr... | 30 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanusertib | AbbVie | Approved | PCSK9 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 |